Immunization News and Research

RSS

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

The new drug nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled phase 3 clinical trial published in the New England Journal of Medicine.

9 Mar 2022

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Researchers assessed the levels of neutralizing antibodies in coronavirus disease patients.

9 Mar 2022

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Researchers developed a vaccine candidate termed Ad26.COV2.S.529, encoding a stabilized Omicron-based S protein resembling ancestral SARS-CoV-2 Wuhan-Hu-1 S protein.

8 Mar 2022

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Researchers developed a highly thermo-tolerant vaccine candidate that elicited high nAb titers in mice against several SARS-CoV-2 variants of concerns.

8 Mar 2022

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

Researchers compared the immunogenicity of the reduced and standard doses of the BNT162b2 and mRNA-1273 vaccine in adults immunized with two doses of the CoronaVac vaccine.

8 Mar 2022

French study shows COVID vaccine efficacy 94% against severe outcomes

A recent paper published on the medRxiv preprint server utilized data from three national databases containing an abundance of information on Covid-19 screening (SI-DEP), vaccination (VAC-SI), and hospitalizations (SI-VIC) in France to provide additional perspectives on vaccine effectiveness and its evolution over the year 2021 in the French context.

7 Mar 2022

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled Phase 3 clinical trial.

3 Mar 2022

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

A new study assesses breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis.

3 Mar 2022

$The benefits of using fractional doses of COVID-19 vaccines$

The benefits of using fractional doses of COVID-19 vaccines

A new study published in PNAS assessed the benefits of using fractional doses for curbing the current COVID-19 pandemic.

3 Mar 2022

First dose SARS-CoV-2 vaccination coverage among younger children in America

Researchers recently investigated the differences in first dose coverage of coronavirus disease 2019 vaccination among children aged five to 11 years in the United States.

3 Mar 2022

How effective is mRNA vaccination in multiple myeloma patients?

In a new study, researchers have been investigating the protection offered by the SARS-CoV-2 vaccine in patients suffering from multiple myeloma.

2 Mar 2022

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

A new study identifies the antigenic differences that exist between the Omicron BA.2 and BA.1 variants.

2 Mar 2022

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

The current study discusses a reliable ELISA that can detect three isotypes of antibody against three SARS-CoV-2 antigens.

2 Mar 2022

Study reports substantial loss of protection one month after complete SARS-CoV-2 BNT162b2 immunization in children

A new study evaluated the efficacy of Pfizer’s BNT162b2 vaccine in children aged 17 years or younger after the emergence of the SARS-CoV-2 Omicron variant.

2 Mar 2022

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of three candidate vaccines, ED88, ED90, and ED94, to select the most appropriate one for future development.

1 Mar 2022

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Immunization News and Research

Single dose of new drug nirsevimab provides safe protection against RSV in healthy infants

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Omicron-based vaccine candidate generated to assess whether immunogenicity could be further improved

Thermostable next-generation vaccine candidate against SARS-CoV-2 variants of concern studied in mice

Comparative immunogenicity of reduced and standard BNT162b2 and mRNA-1273 boosters in CoronaVac vaccinees

French study shows COVID vaccine efficacy 94% against severe outcomes

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

The benefits of using fractional doses of COVID-19 vaccines

First dose SARS-CoV-2 vaccination coverage among younger children in America

How effective is mRNA vaccination in multiple myeloma patients?

Antigenic differences between Omicron BA.1 and BA.2 SARS-CoV-2 variants

Serological test to assess presence of immunoglobulin isotypes targeted against antigens routinely used in COVID-19 diagnosis

Study reports substantial loss of protection one month after complete SARS-CoV-2 BNT162b2 immunization in children

Recombinant adenovirus vector vaccine generates mucosal antibodies against SARS-CoV-2

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Assessing COVID-19 vaccination preferences of younger adults in Canada

Health events amongst pregnant females after COVID-19 vaccination

Triple antibody cocktail is a promising candidate for immunotherapy against SARS-CoV-2 variants of concern

The need for a holistic and unbiased approach to develop a more universal vaccine for coronaviruses

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News